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Assessment of Bronchial and Pulmonary Blood Supply in
Non–Small Cell Lung Cancer Subtypes Using Computed
Tomography Perfusion
Thi Dan Linh Nguyen-Kim, MD,* Thomas Frauenfelder, MD,* Klaus Strobel, MD,†
Patrick Veit-Haibach, MD,*‡ and Martin W. Huellner, MD‡§
Objectives: The aim of this study was to investigate the dual blood supply of
non–small cell lung cancer (NSCLC) and its association with tumor subtype,
size, and stage, using computed tomography perfusion (CTP).
Materials and Methods: A total of 54 patients (median age, 65 years; range,
42–79 years; 15 women, 39 men) with suspected lung cancer underwent a CTP
scan of the lung tumor. Pulmonary and bronchial vasculature regions of interest
were used to calculate independently CTP parameters (blood flow [BF], blood
volume [BV], and mean transit time [MTT]) of the tumor tissue. The mean and
maximum pulmonary and bronchial perfusion indexes (PImean and PImax) were
calculated. The tumoral volume and the largest tumoral diameter were assessed.
Differences in CTP parameters and indexes among NSCLC subtypes, tumor
stages and tumor dimensions were analyzed using non-parametric tests.
Results: According to biopsy, 37 patients had NSCLC (22 adenocarcinomas
[ACs], 8 squamous cell carcinomas [SCCs], 7 large-cell carcinomas [LCC]).
The mean bronchial BF/pulmonary BF, bronchial BV/pulmonary BV, and bron-
chial MTT/pulmonary MTT was 41.2 ± 30.0/36.9 ± 24.2 mL/100 mL/min,
11.4 ± 9.7/10.4 ± 9.4 mL/100 mL, and 11.4 ± 4.3/14.9 ± 4.4 seconds, respec-
tively. In general, higher bronchial BF than pulmonary BF was observed in
NSCLC (P = 0.014). Using a tumoral volume cutoff of 3.5 cm3, a significant dif-
ference in pulmonary PImax was found (P = 0.028). There was a significantly
higher mean pulmonary BF in LCCs and SCCs compared with ACs (P =
0.018 and P = 0.044, respectively), whereas the mean bronchial BF was only sig-
nificantly higher in LCCs compared with ACs (P = 0.024). Correspondingly, the
PImax was significantly higher in LCCs and SCCs than in ACs (P = 0.001 for
both). Differences between bronchial and pulmonary PImean and PImax among
T stages and Union Internationale Contre le Cancer stages were not statistically
significant (P values ranging from 0.691 to 0.753).
Conclusions: The known dual blood supply of NSCLC, which depends on tumor
size and histological subtype, is reflected in CTP parameters, with parameters de-
pending both on tumor size and histological subtype. This has to be accounted for
when analyzing NSCLC with CTP.
Key Words: computed tomography, perfusion, lung neoplasms, multimodal
imaging, medical oncology
(Invest Radiol 2015;00: 00–00)
T hroughout the world, lung cancer still accounts for more deathsthan any other cancer does. More than 200,000 new cases and
approximately 160,000 deaths, accounting for more than one quarter
of all cancer-related deaths, are expected in the United States for
2014.1 Non–small cell lung cancer (NSCLC) constitutes most of lung
cancer. In most patients, the disease is already advanced at the time of
the initial diagnosis, and hence, palliative radiation therapy and chemo-
therapy are initiated as first-line regimens.2,3 The proliferation of new
blood vessels, originating from the existing vascular system, is needed
both for tumor growth and metastatic dissemination.4–6 Monoclonal an-
tibodies, such as bevacizumab, targeting vascular endothelial growth
factor to inhibit tumoral angiogenesis, suppress tumor growth. Such
targeted drugs are increasingly used in combination with standardized
platinum-based chemotherapy.2,7 Patient treatment hence becomes more
individualized to tumor biology, taking into account angiogenic status,
which still needs to be learned and understood.7,8 The traditional moni-
toring of therapeutic effects, being based on morphological criteria
on computed tomography (CT), may lead to a misinterpretation of
antiangiogenic effects.9,10 Hence, the evolving therapeutic field of
vascular-modulating drugs requires new noninvasive methods for as-
sessing tumor vascularity in vivo.11–15
In 1967,Milne16 showed that lung tumors may have a dual blood
supply by the pulmonary and the aortic system, with a trend toward his-
tological type-specific circulatory pattern. The advent of CT perfusion
(CTP) within the last decade allowed for a direct, noninvasive quantifi-
cation of the vascular function.17,18 Functional parameters, derived
from the assessment of peak tumor enhancement over time in the tissue
during the CTP scan, give information about blood volume (BV), blood
flow (BF), and mean transit time (MTT) within the network of tumoral
neovascularity, as well as the rate of abnormal leakage into the extracel-
lular space, due to the vascular hyperpermeability in the abnormal
neovessel wall.5,19 One of the first applications for the assessment of
lung lesions with CTP was pulmonary nodules, particularly in compar-
isonwith 18F-fluoro-2-deoxy-D-glucose positron emission tomography/
CT (PET/CT).20 Cutoff values have been defined for several CTP pa-
rameters to differentiate benign from malignant pulmonary nodules,
with lower perfusion index (PI) and higher BF and BVobtained in ma-
lignancy.21,22 Similar accuracy of CTP and fluoro-2-deoxy-D-glucose-
PET/CTwas confirmed in the meta-analysis by Cronin et al.23 Several
studies have addressed differences of CTP parameters among histolog-
ical lung cancer subtypes, assessing them with a single-input CTP anal-
ysis of either the pulmonary or the bronchial arterial system.24–27
Computed tomography perfusion in lung cancer remains a technical
challenge, particularly due to breathing motion over time.28 Further-
more, a true separation of pulmonary and bronchial BF using a CTP
analysis is technically not possible at this time because blood from both
vascular inputs is mixed within lesions at a microscopic level, preclud-
ing both spatial and temporal separation. Despite these difficulties,
Yuan et al22 recently demonstrated that a dual-input maximum slope
CTP analysis is valuable in NSCLC. However, many centers do not ful-
fill the hardware and software requirements for such a dual-input anal-
ysis and rely on either single-input pulmonary or bronchial CTP
assessment. Currently, there is no universally accepted consensus
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regarding intowhich vascular system the arterial input region of interest
(ROI) should be placed,27,29,30 and either method's results are used in-
terchangeably. The differences in pulmonary circulation-derived and
bronchial circulation-derived analyses are still unclear, and a direct
comparison of CTP parameters derived with these two different
methods is problematic. Besides, information about the association of
pulmonary-derived and bronchial-derived CTP parameters with tumor
size, volume, and stage in different NSCLC subtypes is still limited.
We hypothesized that values of CTP parameters obtained by pul-
monary or bronchial analysis might be different depending on tumor
type, stage, and size. Such differences would have to be accounted for
analyzing NSCLC using CTP with either vasculature approach in a
clinical setup. Thus, the purpose of this study was to investigate the rel-
evance of pulmonary and bronchial ROI placement in the CTP assess-
ment of dually blood-supplied NSCLC and its association with
histological subtypes, tumor size, and tumor stage.
MATERIALS AND METHODS
Study Population
A total of 54 patients (median age, 61 years; range, 42–79 years;
15 women, 39 men) with suspected lung cancer being referred to our
PET/CT center for baseline staging were prospectively enrolled in this
ethical committee–approved study between January 2012 and Decem-
ber 2012. All patients provided signed informed consent before the ex-
aminations. All subjects underwent a CTP scan of the suspected lung
tumor. Exclusion criteria were unwillingness to undergo the CTP scan,
renal insufficiency in nondialyzed patients, pregnancy, untreated hyper-
thyroidism, severe respiratory dysfunction, and known previous reac-
tion after administration of iodinated contrast medium. A definitive
histopathological diagnosis was obtained in all subjects by CT-guided
biopsy, bronchofibroscopic biopsy, or tumor resection (median time in-
terval, 6 days after CTP scan; range, 0-18 days). Thirteen patients were
excluded after the scan because histology results revealed lesions other
than NSCLC (small cell lung cancer, 5 patients; inflammatory myo-
fibroblastic pseudotumor, 1 patient; cavitating staphylococcal pneumo-
nia, 1 patient; streptococcal pneumonia, 1 patient; pulmonary sequester,
1 patient; lymphoma, 1 patient; sarcoma, 1 patient; pulmonary hamar-
toma, 1 patient; and tularemia, 1 patient). In 4 patients, the subsequent
combined pulmonary and bronchial CTP analysis was not possible be-
cause of technical problems. Finally, 37 patients were eligible for anal-
ysis. The NSCLC subtype, tumor size, volume, and stagewere recorded
in all patients. The standard of reference consisted of postsurgical histo-
pathology results in 13 subjects, providing of pathological tumor stage.
In the remaining 24 patients, biopsy-derived histopathology and clinical
tumor stage were used.
CT Perfusion Protocol
Patients were advised to resume shallow breathing for the entire
duration of the scan. All scans were performed on a 256-slice CT scanner
(Somatom Definition Flash, Siemens Healthcare, Erlangen, Germany).
The Z-axis scanning length was 7 cm. This relatively large scan length
was chosen to cover the whole tumor as well as major pulmonary and
bronchial vessels in every patient. The tube current was fixed to 100
mAs, and the tube voltage set to 100 kV. An automatic exposure control
was not used. The duration of thewhole CTP scanwas 60 seconds, with a
rotation time of 1 second, and 1 scan per second. The volume CT dose
index and dose-length product were 193.1 mGy and 1707 mGy cm, re-
spectively, corresponding to a calculated effective dose of 23.9 mSv.
The CTP scanning was started with a delay of 3 seconds after the initia-
tion of the injection of 40 mL of iodinated contrast medium (Ultravist
370, Bayer Healthcare, Leverkusen, Germany) at a flow rate of 4.5 mL/s.
The contrast medium was injected into an antecubital vein by a dual-
head pump injection device (Stellant D, Medrad, Warrendale, PA),
followed by a flush of 50 mL of saline at 4.5 mL/s. This rather lengthy
protocol was chosen to ensure a high reproducibility of perfusion pa-
rameters.31 The slice-collimation was set to 64  0.6 mm. The recon-
struction increment was 3 mm with a 5-mm slice width. Image
reconstruction was performed with a 512  512 pixel matrix and me-
dium smooth B30f kernel.
Data Postprocessing and Image Analysis
For postprocessing and analysis, the reconstructed images were
transferred to a commercially available computer workstation with dedi-
cated perfusion software (Leonardo; Syngo Volume Perfusion CT Body,
Siemens Healthcare). All procedures were carried out by 1 board-
certified radiologist (D.N.) with 6 years of experience in chest imaging.
After computerized motion correction, a semiautomatic freehand seg-
mentation of the tumor tissue volume over timewas performed. To inves-
tigate the pulmonary and bronchial CTP parameters independently, an
elliptical ROI was placed in the pulmonary trunk and in the descending
aorta at the level of the bronchial arteries, respectively. If the pulmonary
trunk was not covered by the CTP volume, the left or right pulmonary ar-
tery was chosen. Time density curves of tissue with different peak times
were calculated, depending on whether a pulmonary-based or bronchial-
based examination was performed.
Pulmonary and bronchial CTP parameters, including specifi-
cally the mean BF, BV, andMTTof the tumor tissue, as well as the max-
imum BF (BFmax), were calculated automatically by the software
(Figs. 1–3). The mean PI (PImean) and the maximum PI (PImax) for both
the pulmonary and bronchial blood circulation were calculated accord-
ing to the following formulas:
pulmonaryPImean¼ ðpulmonaryBFð Þ= pulmonaryBFþ bronchialBFÞð Þ
pulmonaryPImax¼ ðpulmonaryBFmaxð Þ= pulmonaryBFmaxþ bronchialBFmaxÞð Þ;
bronchialPImean¼ bronchialBFpulmonaryBFþ bronchialBF
 
; and
bronchialPImax¼ bronchial BFmax
pulmonaryBFmaxþ bronchialBFmax
 
The longest diameter of the tumor was determined based on the mor-
phological CT data set. The tumor volume was segmented semiauto-
matically using a dedicated volumetry software (Myrian, Intrasense,
Paris, France).
Statistical Analysis
All statistical analyses were performed using IBM SPSS Statistics
19.0.1 (SPSS Inc, Chicago, IL). Differences in pulmonary circulation-
derived CTP parameters and bronchial circulation-derived CTP parame-
ters and indexeswere analyzed using theWilcoxon signed-ranks test. Dif-
ferences in CTP parameters and indexes among NSCLC subtypes, tumor
stages, and among small and large tumors were analyzed using the
Wilcoxon signed-ranks test or the Kruskal-Wallis test. Correlation analy-
ses were performed using Spearman correlation coefficient to analyze the
relationship of CTP parameters and indexes with the tumor diameter, tu-
mor volume, T stage, and Union Internationale Contre le Cancer stage.
RESULTS
Histology results revealed that our study cohort consisted of 22
adenocarcinomas (ACs), 8 squamous cell carcinomas (SCCs), and 7
large-cell carcinomas (LCCs). During therapy, 13 patients (8 with AC,
4 with SCC, 1with LCC) underwent curative surgery and adjuvant radio-
chemotherapy, providing pathological TNM status analysis. Thirteen pa-
tients underwent primary curative radiochemotherapy; 10, palliative
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FIGURE 1. Squamous cell carcinoma of the left upper lobe assessed using a bronchial vasculature approach. TheMIP of computed tomography perfusion
over time (A) and color-coded parametric maps for BF (B), BV (C), andMTT (D) are shown. BF indicates blood flow; BV, blood volume;MIP,maximum
intension projection; MTT, mean transit time.
FIGURE 2. Adenocarcinoma of the left upper lobe assessed using a bronchial vasculature approach. The MIP of computed tomography perfusion over
time (A) and color-coded parametric maps for BF (B), BV (C), and MTT (D) are shown. BF indicates blood flow; BV, blood volume; MIP, maximum
intension projection; MTT, mean transit time.
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chemotherapy; and 1, neoadjuvant therapy and surgery. In these 24 pa-
tients, only clinical TNMwas available. The tumor stage was T1 in 4 pa-
tients, T2 in 25 patients, T3 in 4 patients, and T4 in 4 patients. More
detailed characteristics of the study population are given in Table 1.
For all tumors, the mean pulmonary/bronchial BF was 36.9/41.2
mL/100mL/min, the maximum pulmonary/bronchial BFwas 56.4/64.6
mL/100 mL/min, the mean pulmonary/bronchial BV was 10.4/11.4
mL/100 mL, and the mean pulmonary/bronchial MTT was 14.9/
11.4 seconds.
Overall, the bronchial circulation-derived BF was significantly
higher than the pulmonary circulation-derived BF (P = 0.014)
(Table 2). Within the subanalysis of histological subtypes of NSCLC,
only the BFmax of AC was different depending on the type of assess-
ment, albeit with borderline significance (P = 0.049) (Table 2). Such
a trend toward higher bronchial than pulmonary BF could also be seen
for the remaining subgroups SCC and LCC, however, without reaching
statistical significance (P = 0.401 and P = 0.237, respectively). The sig-
nificant differences in MTT measured with both methods (P values
ranging from <0.001 to 0.018) are a direct consequence of our approach
and are listed in Table 2 only for the sake of completeness. A detailed
overview of CTP parameters of NSCLC subtypes is given in Table 3.
Pulmonary- and bronchial-derived BFs were both significantly higher
in LCC than in AC (P = 0.018, P = 0.024, respectively). Pulmonary
PImax was significantly higher in LCC and SCC than in AC (P = 0.001,
each) (Fig. 4). Differences in PImean and PImax among T stages and Union
Internationale Contre le Cancer stages were statistically not significant
(P values ranging from 0.691 to 0.753), as well as differences between
other CTP parameters. Using a volume threshold of 3.5 cm3 (tumors
<3.5 cm3, n =15; tumors >3.5 cm3, n =22), the pulmonary PImax was found
to be significantly different (P = 0.028) (Fig. 5), whereas no differences
were found for the bronchial BFmax and pulmonary BFmax (P = 0.646,
P = 0.805, respectively). Furthermore, no discriminative threshold could
be found for the tumor diameter.
DISCUSSION
It is known that NSCLCs have a dual blood supply, with contri-
butions both from the pulmonary and the bronchial vasculature.16 Con-
sistent with the results of the recent study by Yuan et al,22 our findings
show that, in NSCLC, the bronchial contribution is higher than the pul-
monary contribution. In addition, we have now demonstrated that there
are also differences depending on the NSCLC subtype: LCC shows
higher bronchial and pulmonary BV and BF compared with AC and
SCC. And the pulmonary PImax was found to be significantly higher
in LCC and SCC compared with AC.
In general, higher perfusion is believed to be related to more ag-
gressive tumor features, such as local invasiveness and metastatic capa-
bility. Our results likely reflect the biological nature of LCC, which is
known to be a poorly differentiated tumor and clinically often shows
a similar behavior as small cell lung cancer, concerning its aggressive-
ness and poor long-term survival.32–35 Correspondingly, Fraioli and
FIGURE 3. Squamous cell carcinoma of the left upper lobe assessed using a bronchial vasculature approach. TheMIP of computed tomography perfusion
over time (A) and color-coded parametric maps for BF (B), BV (C), and MTT (D) are shown. BF, blood flow; BV, blood volume; MIP, maximum
intension projection; MTT, mean transit time.
TABLE 1. Characteristics of the Study Cohort (n = 37)
Parameter
Age, median (range), y 68 (51–79)
Sex ratio (female/male) 8/29
BMI, median (range), kg/m2 26.1 (19.5–29.4)
Tumor volume, median (range), cm3 13.2 (0.8–156)
Tumor diameter, median (range), cm 2.78 (1–50.9)
T stage, median (range) 2 (1–4)
UICC stage, median (range) III (I–IV)
BMI indicates body mass index; UICC, Union Internationale Contre le Cancer.
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coworkers36 recently showed that the comparably high BF of LCC
shows the best response of all NSCLC subtypes to antiangiogenic treat-
ment. We found significant differences in pulmonary PImax using a tu-
mor volume cutoff of 3.5 cm3, with higher pulmonary PImax in larger
tumors. This implies an increase in pulmonary blood supply with grow-
ing tumor size. Our findings correspond reasonably to the results of the
study by Kiessling et al,37 who found lower perfusion in tumors larger
than 50 mm3, using a bronchial arterial system analysis. Tumor volume
certainly reflects the actual tumor size more exactly than does the max-
imum diameter alone. Given an ellipsoid-shaped tumor, it is obvious
that the maximum diameter might not correctly reflect the actual tumor
volume.38 This may be one likely reason we could not find a discrimi-
native cutoff for the maximum tumor diameter.
In 1 of the first studies on this topic, Milne16 demonstrated that
the pulmonary circulation supplies the surface of the tumor, whereas
the central portion is supplied by the bronchial artery system. With in-
creasing tumor volume, hypoxia may occur in the central parts of the
tumor as a result of insufficient blood supply due to an increasing dif-
fusion distance between blood vessels and tumor cells,26,39 explaining
the need to recruit additional blood vessels from the pulmonary system,
TABLE 2. CT Perfusion Parameters in All Tumors, Adenocarcinomas, Squamous Cell Carcinomas, and Large-Cell Carcinomas, Stratified by
Pulmonary and Bronchial Vasculature Assessment
Parameter Pulmonary Bronchial P
All tumors (n = 37)
BF, mean ± SD, mL/100 mL/min 36.9 ± 24.2 41.2 ± 30.0 0.014
BFmax, mean ± SD, mL/100 mL/min 56.4 ± 31.7 64.6 ± 8.7 0.071
BV, mean ± SD, mL/100 mL/min 10.4 ± 9.4 11.4 ± 9.7 0.437
MTT, mean ± SD, s 14.9 ± 4.4 11.4 ± 4.3 <0.001
Adenocarcinoma (n = 22)
BF, mean ± SD, mL/100 mL/min 31.3 ± 14.5 35.3 ± 17.7 0.050
BFmax, mean ± SD, mL/100 mL/min 50.5 ± 20.3 83.5 ± 19.3 0.049
BV, mean ± SD, mL/100 mL/min 10.8 ± 10.3 12.0 ± 10.2 0.291
MTT, mean ± SD, s 15.2 ± 4.7 12.3 ± 4.4 0.002
Squamous cell carcinoma (n = 8)
BF, mean ± SD, mL/100 mL/min 33.1 ± 16.7 36.4 ± 16.8 0.401
BFmax, mean ± SD, mL/100 mL/min 46.2 ± 18.6 50.6 ± 19.4 0.263
BV, mean ± SD, mL/100 mL/min 6.4 ± 3.4 6.8 ± 3.2 0.889
MTT, mean ± SD, s 16.1 ± 3.2 11.5 ± 2.9 0.017
Large-cell carcinoma (n = 7)
BF, mean ± SD, mL/100 mL/min 58.8 ± 15.8 66.5 ± 20.9 0.237
BFmax, mean ± SD, mL/100 mL/min 78.8 ± 53.5 82.3 ± 105.6 0.128
BV, mean ± SD, mL/100 mL/min 13.4 ± 10.4 14.4 ± 12.2 0.866
MTT, mean ± SD, s 35.5 ± 21.4 8.6 ± 4.7 0.018
BF indicates blood flow; CT, computed tomography; BV, blood volume; MTT, mean transit time.
TABLE 3. CT Perfusion Parameters Stratified by NSCLC Subtypes
Parameter AC (n = 22) SCC (n = 8) LCC (n = 7) P AC vs SCC AC vs LCC SCC vs LCC
BF bronchial, mean ± SD,
mL/100 mL/min
35.3 ± 17.7 36.4 ± 16.8 66.5 ± 20.9 0.002 0.479 0.024 0.237
BF pulmonary, mean ± SD,
mL/100 mL/min
31.3 ± 14.5 33.1 ± 16.7 58.8 ± 15.8 0.033 0.044 0.018 0.176
BV bronchial, mean ± SD,
mL/100 mL/min
12.0 ± 10.2 6.8 ± 3.2 14.4 ± 12.2 0.001 0.051 0.499 0.128
BV pulmonary, mean ± SD,
mL/100 mL/min
10.8 ± 10.3 6.4 ± 3.4 13.4 ± 10.4 0.007 0.208 0.735 0.091
MTT pulmonary, mean ± SD, s 15.2 ± 4.7 16.3 ± 3.1 12.9 ± 4.8 0.007 0.717 0.326 0.168
MTT bronchial, mean ± SD, s 12.3 ± 4.4 11.5 ± 2.9 8.6 ± 4.7 0.288 0.985 0.236 0.267
Pulmonary PImean, mean ± SD 0.4 ± 0.1 0.5 ± 0.1 0.5 ± 0.1 0.150 0.475 0.750 0.824
Pulmonary PImax, mean ± SD 0.4 ± 0.1 0.5 ± 0.04 0.5 ± 0.08 <0.001 0.001 0.001 0.660
Volume, median (range), cm3 8.9 (0.8–156) 16.3 (2.62–153.0) 13.2 (3.3–32.2) 0.622 0.168 0.328 0.269
Diameter, median (range), mm 4.2 (1.0–5.1) 3.4 (2.0–8.4) 4.6 (2.8–4.9) 0.565 0.103 0.942 0.195
As bronchial PI being defined as 1-pulmonary PI, bronchial PI is not shown in this table.
AC indicates adenocarcinoma; BF, blood flow; BV, blood volume; CT, computed tomography; LCC, large-cell carcinoma; MTT, mean transit time; NSCLC, non–small
cell lung cancer; PI, perfusion index; SCC, squamous cell carcinoma.
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which carries deoxygenated blood but has a much larger cross-sectional
area than the bronchial system does. Hence, our results provide further
evidence for the theory that NSCLCs have a tendency to recruit more
new blood vessels from the pulmonary system than from the bronchial
system to grow. It however remains unclear if growing tumors might
not just surround pulmonary vessels recruiting them, rather than consti-
tuting real angiogenesis originating from pulmonary vessels.
If interventional endovascular therapy is contemplated in an
NSCLC patient, knowledge about the PImax may provide guidance for
choosing a transbronchial or a transpulmonary approach. Transarterial
chemoembolization has been used successfully for years for the treat-
ment of hepatic malignancies40 and has recently gained attention as a
minimally invasive approach for treating NSCLC.41 Recent studies
demonstrated that the transpulmonary chemoembolization of different
malignant lung lesions yielded a favorable tumor response without ma-
jor complications.41–43 It is now considered a well-tolerated palliative
treatment option in patients with lung metastases.44 However, today,
no clear recommendation exists in which case a transpulmonary or
transbronchial approach should be attempted. In this context, our re-
sults would suggest a preferred transpulmonary approach in tumors
larger than 3.5 cm3, especially in LCC and SCC, and a transbronchial
approach in tumors smaller than 3.5 cm3, especially in AC.
Although the response evaluation criteria in solid tumors were
developed to assess tumoral response to cytotoxic agents, these may
not properly reflect tumoral changes because of new antiangiogenic
drugs.7,45 Computed tomography perfusion might represent a clinical
tool to assess the “behavior” of tumoral angiogenesis under targeted
antiangiogenic therapy. This concept has been addressed by several pre-
vious studies.9,15,46–48 Tacelli et al19,36 showed a significant reduction
in total tumor vascular volume during treatment with chemotherapy
using anti–vascular endothelial growth factor drugs. Fraioli et al19,36
demonstrated a significant difference in BF and BV in LCC patients
for partial response and progressive disease. Although we did not ad-
dress therapeutic effects, the results of our study indicate that both his-
tological subtype and tumor volume likely should be taken into account
when assessing tumoral treatment response using CTP. Further studies
are needed to address treatment-induced effects on either blood supply,
to define a potential role of pulmonary and/or bronchial CTP assess-
ment for therapy monitoring.
Because we applied a tube voltage of 100 kVand found no both-
ersome beam-hardening, we believe that the voltage might even be re-
duced further for CTP studies, especially concerning the lung, to
increase the sensitivity to the contrast agent and to reduce both dose ex-
posure and contrast agent administered to the patient.
Our study has several limitations. Our approach was not able to
directly and independently measure the contribution of the pulmonary
and bronchial vasculature to the overall tumor perfusion. This was,
however, not our goal because we aimed at identifying differences in
CTP parameters depending on the type of the arterial input ROI place-
ment. Most of our subjects had AC, which means that the overall results
for NSCLC were dependent largely upon this histological subtype.
This, however, does not affect the subanalyses carried out for all histo-
logical subtypes, although LCC and SCC numbers were comparably
small. Tumor stage was somewhat skewed according to NSCLC sub-
types, with LCC patients having by trend more advanced stages. This
may also have influenced our results. As well, most of the reported tu-
mor stages were clinical and not pathological.
FIGURE 4. Pulmonary PImax of non–small cell lung cancer subtypes. PImax indicates maximum perfusion index.
FIGURE 5. Pulmonary PImax in all tumors, using a volume cutoff of
3.5 cm3. PImax indicates maximum perfusion index.
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CONCLUSIONS
Our study is the first to address differences in the assessment of
NSCLC and its subtypes by CTP, using both a pulmonary and a bron-
chial vasculature approach. The known dual blood supply of NSCLC
is reflected by differences in CTP parameters and depends both on
tumor size and histological subtype. A generally higher bronchial-
derived than pulmonary-derived BF was found in AC, as well as both
higher pulmonary-derived and bronchial-derived BF in LCC compared
with other subtypes. Larger tumors have a higher pulmonary than bron-
chial contribution to their blood supply compared with smaller tumors.
Therefore, a CTP analysis of lung cancer, either in a primary setup or
for the assessment of therapy response, should consider that parameters
cannot simply be translated between NSCLC subtypes as well as be-
tween pulmonary and bronchial approaches. Furthermore, with grow-
ing or regressing tumors, the ratio of pulmonary and bronchial blood
supply as expressed by CTP parameters might vary. This has to be
accounted for when analyzing NSCLC with either a pulmonary or a
bronchial vasculature approach.
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